CNS Disorders
Rare central nervous system (CNS) disorders present unique challenges in both understanding and treatment. At MuriPhys, we specialize in providing advanced preclinical solutions that decode the intricacies of these conditions, accelerating the development of transformative therapies. Our comprehensive approach combines cutting-edge drug delivery technologies, sophisticated behavioral assays, and advanced electrophysiology to bring clarity to the most elusive neurological disorders.
By partnering with MuriPhys, you gain access to unparalleled expertise and the tools necessary to illuminate the pathophysiology of rare CNS diseases, ensuring that no detail is left unexplored.
Disorders We Specialize In:
Huntington’s Disease
MuriPhys provides specialized tools to investigate the progressive neuronal degeneration characteristic of Huntington’s. Our intraparenchymal (IPa) drug delivery directly targets the striatum and cortex—key regions affected by the disease. Complementing this, we offer behavioral assessments such as rotarod, balance beam, and Y-maze, alongside electrophysiological studies (EEG, EMG) to track disease markers and therapeutic efficacy at every stage. Read More.
Ataxia
Ataxia research benefits from MuriPhys’ targeted delivery to the cerebellar cortex and deep nuclei. Our array of behavioral tests assesses gait, balance, and motor coordination, while electrophysiological recordings track cerebellar activity and disease evolution. Read More.
Parkinson’s Disease
Parkinson’s research demands precision and versatility. Our intraparenchymal (IPa) delivery into the substantia nigra, as well as intracerebroventricular (ICV) and intrathecal (IT) options, ensure targeted and systemic drug distribution. Behavioral assays replicate hallmark symptoms, while EEG and EMG studies provide insight into motor and neuromuscular changes over time. Read More.
Amyotrophic Lateral Sclerosis (ALS)
ALS devastates motor neurons, and MuriPhys addresses this with IPa and ICV delivery focused on the motor cortex and spinal cord. Our assays, including open field and OCT imaging, capture the progression of muscle atrophy and coordination deficits, enabling the rigorous evaluation of novel therapeutics. Read More.
Dementias
From Alzheimer’s to Lewy Body and Frontotemporal Dementia, MuriPhys provides comprehensive tools to dissect the complexities of cognitive decline. Our drug delivery platforms span intraparenchymal, ICV, and IT routes, facilitating localized and systemic targeting. Behavioral assays explore memory and learning, while EEG recordings highlight neuronal dysfunction, offering crucial biomarkers for early detection and progression tracking. Read More.
Rett Syndrome
Rett Syndrome disrupts normal neural development, leading to severe motor and cognitive impairments. MuriPhys addresses this complex disorder with targeted intraparenchymal (IPa), intracerebroventricular (ICV), and intrathecal (IT) drug delivery, ensuring precise intervention at the cortical and spinal levels. Our behavioral assays, including rotarod and open field tests, monitor motor dysfunction, while EEG and EMG recordings track seizure activity and neurological decline, providing comprehensive data for therapeutic assessment. Read More.
Fragile X Syndrome
Fragile X, the leading inherited cause of intellectual disability, requires specialized models that capture both cognitive and behavioral symptoms. MuriPhys’ CNS and systemic delivery methods, from IPa to ICV and IT, facilitate targeted treatment evaluations. Our behavioral tests encompass learning, social interaction, and sensory processing assessments, while electrophysiology provides insights into neural excitability and synaptic dysfunction, ensuring a holistic approach to drug development.
Angelman Syndrome
Characterized by severe developmental delays, motor dysfunction, and epilepsy, Angelman Syndrome benefits from MuriPhys’ advanced delivery techniques. Our team leverages intraparenchymal and systemic methods to precisely target key brain regions. In addition to rotarod and Y-maze assays, optodrum and OCT imaging capture motor and vision-related deficits. EEG monitoring further tracks seizure progression, ensuring a complete picture of disease evolution.
Tourette Syndrome
Tourette Syndrome’s complex interplay of motor and vocal tics requires diverse preclinical tools. MuriPhys’ delivery systems, including IPa and ICV methods, allow targeted drug administration to critical brain regions. Behavioral assays replicate tic phenotypes, while EEG data reveals the neural activity driving involuntary movements. Our models ensure that potential therapies address both the neurological and behavioral dimensions of the disorder.
Download our white paper
Why MuriPhys for Rare CNS Disorders?
- Tailored Delivery Systems: MuriPhys offers precision delivery platforms designed to reach the most elusive areas of the CNS, ensuring targeted and effective therapeutic application.
- Diverse Behavioral Assays: From social interaction paradigms to motor coordination tests, our comprehensive suite of behavioral assessments reflects the full clinical presentation of rare CNS disorders.
- Electrophysiological Expertise: EEG and EMG recordings uncover critical biomarkers and track disease progression, providing invaluable insights into therapeutic efficacy.
- Comprehensive Approach: Rare CNS disorders require nuanced, multi-faceted strategies. Muriphys customizes every aspect of the study to align with the unique needs of each condition, driving deeper understanding and faster breakthroughs.
Muriphys stands at the forefront of rare CNS disorder research, offering the tools and expertise necessary to unlock new therapeutic possibilities.
Partner with us to transform the landscape of rare CNS disease research—where precision drives progress and innovation shapes the future.